FierceBiotechOriginal article
{"a":[{"_":"Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx","$":{"href":"/biotech/latigo-laces-247m-ipo-fund-non-opioid-pain-drug-rival-vertexs-journavx","hreflang":"en"}}]}
IPO/OfferingJournavxPositive
AI Analysis
Summary
Latigo Biotherapeutics announced plans for a $247M IPO to fund development of its clinical-stage non-opioid pain management drug pipeline, positioning itself as a competitor to Vertex's Journavx.
Importance:6/10
Sentiment:
0.60
IPOnon-opioid painclinical-stagefundraising
Related Companies
Read the original article
Published by FierceBiotech on August 4, 2026 7:56 AM
